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BCR-ABL activity and its response to drugs can be determined in CD34þ CML stem cells
by CrkL phosphorylation status using flow cytometry
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In chronic myeloid leukaemia, CD34þ stem/progenitor cells
appear resistant to imatinib mesylate (IM) in vitro and in vivo. To
investigate the underlying mechanism(s) of IM resistance, it is
essential to quantify Bcr-Abl kinase status at the stem cell level.
We developed a flow cytometry method to measure CrkL
phosphorylation (P-CrkL) in samples with o104 cells. The
method was first validated in wild-type (K562) and mutant
(BAF3) BCR-ABLþ as well as BCR-ABL (HL60) cell lines. In
response to increasing IM concentration, there was a linear
reduction in P-CrkL, which was Bcr-Abl specific and correlated
with known resistance. The results were comparable to
those from Western blotting. The method also proved to
be reproducible with small samples of normal and Phþ
CD34þ cells and was able to discriminate between Ph,
sensitive and resistant Phþ cells. This assay should now
enable investigators to unravel the mechanism(s) of IM
resistance in stem cells.
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Introduction
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative
disorder of haemopoietic stem cells, characterised by the
reciprocal translocation between chromosomes 9 and 22.1 This
translocation generates the oncogenic bcr-abl fusion gene,
which encodes a protein that demonstrates higher and
constitutively active tyrosine kinase activity compared with the
normal Abl counterpart.2 Although Bcr-Abl is known to play a
central role in the pathogenesis of CML, the specific mechan-
isms by which it mediates the disease are still unclear. However,
there is evidence that it induces tyrosine phosphorylation of
downstream signalling substrates, including CrkL. CrkL is the
major tyrosyl-phosphoprotein detected in the peripheral blood
cells of patients with CML, suggesting that its association with
Bcr-Abl plays an important role in the pathogenesis of the
disease.3–5 The specificity of CrkL phosphorylation to Bcr-Abl
signalling, partnered with the stability of the phosphoprotein
complex, has led to its acceptance as an excellent method to
assess Bcr-Abl status.6,7 CrkL phosphorylation has previously
been determined by Western blot in Bcr-Abl-expressing cell
lines and primary CML cells; however, this method is time
consuming and requires large numbers of cells, which are
difficult to obtain from primary cell samples. As part of our
efforts to characterise CML stem cells,8–11 we have now developed
a method to detect phosphorylated CrkL by flow cytometry, using
an anti-phospho-CrkL (P-CrkL) antibody, requiring minimal cell
numbers from patient samples.
Materials and methods
Reagents
Imatinib mesylate (IM) was a gift from Novartis Pharma (Basle,
Switzerland).
Cell lines
The BCR-ABL-positive K562 and BCR-ABL-negative HL60 cell
lines were grown in suspension in RPMI 1640 (Sigma-Aldrich
Company Ltd, Dorset, UK) with 10% fetal calf serum (Invitro-
gen, Paisley, UK), 1% glutamine (100 mM) and 1% penicillin–
streptomycin (100 mM) (Invitrogen) (RPMIþ ), in a humidified
incubator at 371C in an atmosphere of 5% (v/v) CO2. Every 3–4
days, cells were counted using a haemocytometer and set up at
1 106 cells per 75 cm2 flask with fresh RPMIþ . BA/F3 cells
containing wild-type or Bcr-Abl with kinase domain mutations
were maintained in RPMIþ supplemented with 10% condi-
tioned medium from WEHI-3B cells.
Primary cell samples of fresh leukapheresis products from
patients with chronic-phase CML, before any exposure to IM
in vivo, or from patients undergoing autologous stem cell
transplantation, were enriched for CD34þ cells using a clinical
scale method of magnetic-activated cell sorting – CLINIMACS
(Miltenyi Biotec Ltd, Bisley, UK). The selected cells were then
cryopreserved in 10% (v/v) dimethyl sulfoxide in ALBA (4%
(w/v) Human Albumin Solution, Scottish National Blood
Transfusion Service, Edinburgh, UK) and stored in the vapour
phase of liquid nitrogen until required. All human cell samples
were obtained with informed consent. Cells were cultured in
Iscove’s modified Dulbecco’s medium (Sigma) supplemented
with a serum substitute (BIT; StemCell Technologies, Vancou-
ver, Canada), 0.1 mM 2-mercaptoethanol (Sigma), 1% glutamine
(100 mM) and 1% penicillin–streptomycin (100 mM) (serum-free
medium, SFM). Serum-free medium was further supplemented
with a five growth factor cocktail comprising 100 ng/ml Flt3-
ligand and 100 ng/ml stem cell factor and 20 ng/ml each of
interleukin (IL)-3, IL-6 (all from StemCell Technologies) and
granulocyte colony stimulating factor (Chugai Pharma Europe
Ltd, London, UK).
CrkL phosphorylation assay
Cell lines were incubated with increasing concentrations of IM
for 16 or 48 h, with drug replenished after 24 h. CD34þ cells
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were incubated with 5 mM IM for 16 or 72 h, with drug
replenished within 24 h of the end of assay. The later time
point differed for K562 and CD34þ cells, as K562 are more
sensitive to IM and undergo apoptosis by 48 h, whereas CD34þ
cells require 72 h. HL60 cells were used as BCR-ABL-negative
controls for K562 and BA/F3 cells and Ph CD34þ cells were
used as BCR-ABL-negative controls for CD34þ CML cells. For
each data point, X1 104 cells were re-suspended in 100ml
Fixing Reagent (‘Fix and Perm’ kit, CALTAG Laboratories,
Silverstone, UK), incubated at room temperature (RT) for
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Figure 1 Effect of increasing concentrations of imatinib mesylate (IM) on K562 and HL60 cell lines and chronic myeloid leukaemia (CML)
CD34þ cells. K562 and HL60 cells were cultured7increasing concentrations of IM (0.1, 0.5, 1, 5 and 10mM) for 48 h. Intracellular flow cytometry
was used to measure P-CrkL status at 16 and 48 h. Panel a shows that IM had no effect on P-CrkL status in the Bcr-Abl-negative cell line, HL60.
Panel b demonstrates the dose-dependent decrease in P-CrkL in IM-treated K562 cells. Panel c shows Western blot for cells treated with increasing
concentrations of IM for 16 h (K562, HL60 and CML CD34þ ) and 72 h (CD34þ only). The blot was reprobed with anti-pan-actin antibody to
confirm equal sample loading. Panel d demonstrates the equivalence between flow cytometry and Western blot methods, in P-CrkL reduction in
K562 cells after 48 h treatment with IM.
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15 min, washed with 3 ml phosphate-buffered saline (PBS)/1%
bovine serum albumin (BSA)/0.1% sodium azide and centri-
fuged at 1000 rpm for 5 min. Twenty-five microlitres of
Permeablising Reagent (CALTAG Laboratories) were added to
the cell pellet with 2.5 ml of P-CrkL-specific antibody (New
England Biolabs (UK) Ltd, Hitchin, UK) and the cells were
vortexed and incubated at RT for 40 min. The wash step was
repeated twice, the cells were re-suspended in 100ml PBS/BSA/
sodium azide and the secondary antibody (anti-rabbit IgG FITC-
conjugate (Sigma)) and incubated at RT for 30 min in the dark.
The wash step was repeated twice and the samples were
analysed by flow cytometry. Isotype controls were included for
cytometer set-up. The assay was also run on fresh compared to
cryopreserved aliquots of the same samples to confirm that
P-CrkL baseline levels were unchanged by cryopreservation
(data not shown).
The amount of P-CrkL in the sample was determined as the
geometric mean fluorescence intensity (MFI) of the P-CrkL-
labelled untreated sample minus the MFI of the BCR-ABL-
negative control (baseline P-CrkL). The P-CrkL status of the IM-
treated samples was expressed as a percentage of the untreated
control (100%).
K562 Western blot and HL60 were cultured in the presence or
absence of IM for 48 h. CD34þ CML cells were cultured in the
presence or absence of IM for 16 and 72 h. Western blot was
performed using standard techniques with the same specific
anti-P-CrkL primary antibody (1:1000) (New England Biolabs) as
used in flow cytometry and an anti-rabbit IgG, horseradish
peroxidase-linked secondary antibody (1:3000) (New England
Biolabs). The membranes were then stripped in 1 ‘Re-Blot
Plus Strong Antibody Stripping Solution’ (Chemicon, Hamp-
shire, UK) for 15 min at RT and re-probed with anti-pan-actin
antibody (1:1000) (New England Biolabs) in 5% BSA/phosphate-
buffered saline with BSA, to confirm equal sample loading.
Developed films were scanned with an Epson scanner and the
integrated density of protein bands was determined with
ImageQuant software (Molecular Dynamics). Densitometry data
were normalised so that the untreated control had 100% P-CrkL
and the result from each IM-treated sample was calculated
based on this.
Results and discussion
Effect of IM on CrkL phosphorylation in K562, HL60 and
BAF3-BCR-ABL cells
In order to determine Bcr-Abl kinase status in response to IM
treatment in rare stem cell populations, we first validated an
intracellular flow cytometry assay measuring P-CrkL in the BCR-
ABL-positive cell line K562 and the BCR-ABL-negative cell line
HL60. IM treatment of HL60 cells had no effect on baseline
P-CrkL status at either 16 or 48 h (Figure 1a). Figure 1b and its
corresponding MFI data presented in Table 1 show that IM-
treated K562 cells demonstrated a dose-dependent decrease of
P-CrkL, with only 16.6% phosphorylation after 48 h treatment
with 10mM IM, as compared to no drug control (100%). To
prove the specificity of the P-CrkL antibody in the flow
cytometry-based detection method, the effect of IM on P-CrkL
was also assessed by Western blot on K562, HL60 and CML
CD34þ cells. Figures 1c and d confirm the results from the flow
cytometry assay, showing that increasing concentrations of IM
reduced expression of P-CrkL in a dose-dependent manner in
K562 cells. Further, following 16 h treatment with the highest
clinically achievable dose of IM,12 P-CrkL was inhibited in CML
CD34þ cells. However, after 72 h treatment, the surviving stem
cells (42.7% in the case shown in Figure 1c and mean 31.3%
(n¼ 8)) showed increased expression of P-CrkL. The overall
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Figure 2 Effect of increasing concentrations of imatinib mesylate (IM) on BAF3 cell lines with defined Bcr-Abl kinase mutations. BAF3-BCR-ABL
wild type, M351T (low-level IM resistance), H396P (intermediate IM resistance) and T315I (high IM resistance) were cultured7increasing
concentrations of IM (1, 5, 10 and 20mM) for 16 h. P-CrkL levels were then determined by intracellular flow cytometry. A variable P-CrkL response,
which correlated with each BAF3-BCR-ABL mutant’s degree of IM resistance is demonstrated.
Table 1 MFI values and corresponding % P-CrkL for K562 cells
after 48 h treatment with increasing doses of IM
IM (mM) MFI – Ph % P-CrkL
0 55.26 100
0.1 43.65 79
0.5 29.08 52.6
1 16.71 30.24
5 11.07 20
10 9.18 16.6
Abbreviations: IM, imatinib mesylate; MFI, mean fluorescence intensity.
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CD34þ protein level (actin loading control) at 72 h was lower
owing to the decrease in overall cell number. P-CrkL expression
was not evident in HL60 cells.
We next investigated how cell lines with verified resistant
phenotypes would perform in this assay. BAF3-BCR-ABL wild
type, M351T (low-level IM resistance), H396P (intermediate IM
resistance) and T315I (high IM resistance) were compared for
P-CrkL inhibition at 16 h after IM exposure. As shown in
Figure 2, the individual cell lines could be identified by their
differing degrees of resistance as was expected from their known
mutations.13
Effect of IM treatment on primary CD34þ CML cells
Previous investigators have demonstrated the differences in total
phosphotyrosine inhibition between CD34þ cells from cyto-
genetic responders and non-responders to IM treatment.14
Therefore, to more directly assess Bcr-Abl kinase activity in
response to IM treatment, we cultured CD34þ cells from normal
donors and CML patients (n¼ 8) in the presence and absence of
5mM IM for 72 h. P-CrkL was measured at 16 h to determine the
immediate effects on P-CrkL, and at 72 h, in order to examine
the P-CrkL status in those cells that survived drug treatment.
Figure 3a demonstrates the P-CrkL profile of the only CML
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Figure 3 Effect of imatinib mesylate (IM) treatment on CD34þ chronic myeloid leukaemia (CML) cells. CD34þ CML cells (n¼8) were cultured
75 mM IM for 72 h. P-CrkL status was measured in each of the samples at 16 and 72 h. Panel a demonstrates the P-CrkL profile from the only ‘non-
responder’ to IM in this series. At both 16 and 72 h, IM-treated CD34þ CML cells showed maximal phosphorylation of CrkL, as compared to no
drug control (100%). Panel b shows a representative profile from a ‘responder’ to IM. After 16 h, there was only a 7% expression of P-CrkL in
IM-treated CD34þ CML cells, whereas, at 72 h, there was no decrease in the phosphorylation of CrkL in these cells, as compared to no drug
control (100%). Panels c and d demonstrate dot plots of CD34þ CML cells, control and treated with 5 mM IM, respectively, for 72 h. The three cell
populations are denoted as follows: *drug resistant; **drug sensitive; ***BCR-ABL negative. Panel e shows the overlay of the IM-treated cells from
Panel d (light grey) with an untreated control (dark grey). The three cell populations (*, ** and ***) are as above.
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patient in this series of eight who did not respond optimally to
IM treatment (i.e. did not achieve cytogenetic response by 6
months). After both 16 and 72 h, IM-treated CD34þ CML cells
showed no reduction in P-CrkL, consistent with the presence of
IM-resistant cells. We were unable to demonstrate the presence
of a known IM resistance mutation for this case at diagnosis
using direct sequencing, consistent with the literature,15,16 and
by Double-fluorescent in situ hybridisation, there was no
evidence of BCR-ABL amplification, either in the starting
population of CD34þ cells or after drug exposure. Figure 3b
shows a representative P-CrkL profile of a CML patient who
responded well to IM treatment (i.e. complete haematological
remission by 4 weeks and complete cytogenetic remission by 6
months). This was the pattern seen for seven of the eight cases.
After 16 h, there was only 7% phosphorylation of CrkL in IM-
treated CD34þ CML cells, relative to no drug control (100%),
indicating that most of the cells were sensitive to IM. However,
after the 72 h time point, the cells that had survived IM treatment
demonstrated a return to baseline of P-CrkL. This suggests that
following the death of IM-susceptible CD34þ CML cells, there
was enrichment for an IM-resistant cell population. Figures 3c–e
demonstrate the heterogeneity of response to IM treatment in
CD34þ CML cells. Rather than producing the expected single
P-CrkL peak, in the absence of IM, three different peaks were
evident in this profile, suggesting the presence of three cell
populations within the CML sample (Figure 3c). This patient was
diagnosed early with total WBC of only 18 109/l. Baseline
cytogenetics confirmed a significant proportion (40%) of Ph
metaphases. Following IM treatment, a clear population shift
was evident (Figure 3d). The population with medium intensity
antibody staining (**) after exposure to IM was IM responsive,
with significant reduction in P-CrkLs from baseline, relative to
the untreated control (Figure 3c). It is probable that the
population denoted (***) therefore represented normal Ph
CD34þ cells, whereas the cells with highest intensity staining
(*) proved to be IM resistant.
Overall, these results validate a rapid method to detect P-CrkL
protein at the single cell level by flow cytometry. The minimum
number of cells may be reduced to o104 for test and control,
enabling an accurate assessment of Bcr-Abl kinase activity in
rare stem cell populations in response to novel tyrosine kinase
inhibitors.
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